PRGN-3006

N/A

Report date: 2025/02/08 10:33:13

First In Class

Base Information

Drug NamePRGN-3006

Drug Alias NamePRGN-3006PRGN-3006 UltraCAR-T

ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacementsMyeloid cell surface antigen CD33 inhibitors

TargetsMyeloid cell surface antigen CD33

Therapy Area/IndicationsMyelodysplastic SyndromesLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesPrecigen Inc

China Registration ClassN/A

Develop Information

Active CompaniesPrecigen Inc

Inactive CompaniesN/A

Active IndicationsMyelodysplastic SyndromesLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A